This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ligand Pharmaceuticals (LGND) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Ligand (LGND) delivered earnings and revenue surprises of 53.85% and 46.78%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
LGND or RGEN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LGND vs. RGEN: Which Stock Is the Better Value Option?
Blueprint Medicines Files NDA to FDA for Pralsetinib in MTC
by Zacks Equity Research
Blueprint Medicines (BPMC) files an NDA to the FDA for pralsetinib to treat patients with advanced/metastatic RET mutant medullary thyroid cancer and RET fusion-positive thyroid cancers. Stock up.
Ultragenyx's Dojolvi Gets FDA Nod to Treat Rare Disease
by Zacks Equity Research
Ultragenyx (RARE) gets FDA approval forDojolvi for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders.
Axsome's AXS-05 Gets Breakthrough Therapy Tag for AD Agitation
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy status on Axsome's (AXSM) AXS-05 for the treatment of Alzheimer's disease agitation. Shares rise.
Ascendis Submits BLA to FDA for TransConhGH in Pediatric GHD
by Zacks Equity Research
Ascendis Pharma (ASND) submits BLA to the FDA for TransConhGH for the treatment of pediatric growth hormone deficiency.
Vertex's Triple Combo Cystic Fibrosis Pill Gets CHMP Backing
by Zacks Equity Research
Vertex (VRTX) is seeking approval in Europe for its triple combo pill, Kaftrio in combination with Kalydeco to treat cystic fibrosis in patients aged 12 and older with most common genotypes.
Gilead to Buy 49.9% Stake in Private Biotech for $275M
by Zacks Equity Research
Gilead (GILD) to purchase 49.9% equity interest in privately-held Pionyr Immunotherapeutics. The company can later also exercise an option to acquire the rest of Pionyr.
Biogen Falls on Patent Loss of MS Drug Tecfidera to Mylan
by Zacks Equity Research
The U.S. District Court of West Virginia gives a ruling against Biogen (BIIB) over a patent dispute with generic drugmaker Mylan pertaining to its best-selling multiple sclerosis drug, Tecfidera.
Protagonist Therapeutics' PTG-300 Gets FDA's Orphan Drug Tag
by Zacks Equity Research
The FDA bestows an orphan drug status on Protagonist Therapeutics' (PTGX) PTG-300 injection for treating patients with polycythemia vera. It is also being developed for hereditary hemochromatosis.
LGND or RGEN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LGND vs. RGEN: Which Stock Is the Better Value Option?
ACADIA Files sNDA for Nuplazid in Dementia-Related Psychosis
by Zacks Equity Research
ACADIA (ACAD) files an sNDA for Nuplazid's potential second indication to treat hallucinations and delusions linked to dementia-related psychosis.
Immunic Gets FDA Allowance for Phase II Coronavirus Study
by Zacks Equity Research
Immunic (IMUX) gets a FDA allowance to begin a phase II study on its DHODH inhibitor IMU-838 for addressing COVID-19 in the United States. Top-line results on the same are awaited later this year.
Vertex's Kalydeco Wins Approval in EU for CF in Children
by Zacks Equity Research
Vertex's (VRTX) Kalydeco gains EU nod for use in cystic fibrosis patients aged from six months to 18 years with the R117H mutation in the CFTR gene.
Why Is Ligand (LGND) Up 16.3% Since Last Earnings Report?
by Zacks Equity Research
Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
LGND or TECH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LGND vs. TECH: Which Stock Is the Better Value Option?
Should Value Investors Buy Ligand Pharmaceuticals (LGND) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
LGND vs. TECH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LGND vs. TECH: Which Stock Is the Better Value Option?
Ligand (LGND) Beats on Q1 Earnings & Sales, Raises View
by Zacks Equity Research
Ligand (LGND) reports higher-than-expected first-quarter 2020 earnings and revenues.
Ligand Pharmaceuticals (LGND) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Ligand (LGND) delivered earnings and revenue surprises of 45.90% and 27.30%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Ligand Pharmaceuticals (LGND) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Ligand (LGND) Stock?
by Zacks Equity Research
Investors need to pay close attention to Ligand (LGND) stock based on the movements in the options market lately.
Ligand (LGND) Up 16.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ligand (LGND) Q4 Earnings & Revenues Top Estimates, Stock Up
by Zacks Equity Research
Ligand (LGND) reports higher-than-expected fourth-quarter 2019 earnings and revenues.
Ligand Pharmaceuticals (LGND) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Ligand (LGND) delivered earnings and revenue surprises of 4.41% and 8.27%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?